Abstract
From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post-coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti-SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post-COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products.
Keywords: COVID-19; CoVIg-19; Primary immunodeficiency; SARS coronavirus 2 antibody potency; SARS-CoV-2; Secondary immunodeficiency; hyperimmune globulin; immunoglobulin; intravenous immune globulin; neutralizing antibodies; plasma; prophylaxis.
【저자키워드】 COVID-19, SARS-CoV-2, Neutralizing antibodies, Primary Immunodeficiency, Prophylaxis, Immunoglobulin, plasma, secondary immunodeficiency, intravenous immune globulin, CoVIg-19, hyperimmune globulin, SARS coronavirus 2 antibody potency, 【초록키워드】 neutralizing antibody, coronavirus, antibody, anti-SARS-CoV-2, immune, Prophylaxis, SARS-CoV-2 antibody, Antibody titer, Neutralizing, donors, SARS Coronavirus, correlation, disease, Donor, intravenous, acute respiratory syndrome, secondary, hyperimmune, produced, predicted, addition, vaccinated against COVID-19, 【제목키워드】 potent, donation,